Q3 Earnings Estimate for Immuneering Issued By HC Wainwright

Immuneering Corporation (NASDAQ:IMRX) – Equities research analysts at HC Wainwright issued their Q3 2026 EPS estimates for Immuneering in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($0.31) for the quarter. HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Immuneering’s Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($1.22) EPS, FY2028 earnings at ($1.30) EPS, FY2029 earnings at ($1.32) EPS and FY2030 earnings at ($0.40) EPS.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01).

A number of other equities research analysts also recently issued reports on IMRX. Oppenheimer restated an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. Chardan Capital upgraded shares of Immuneering to a “strong-buy” rating in a research note on Monday, August 3rd. Cantor Fitzgerald initiated coverage on shares of Immuneering in a research note on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Wednesday, June 24th. Finally, UBS Group set a $14.00 price objective on Immuneering in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Immuneering presently has an average rating of “Buy” and an average target price of $17.50.

Immuneering Stock Performance

IMRX stock opened at $4.80 on Monday. Immuneering has a fifty-two week low of $2.90 and a fifty-two week high of $10.08. The business’s 50-day moving average is $4.57 and its two-hundred day moving average is $4.98. The company has a market cap of $310.56 million, a price-to-earnings ratio of -4.62 and a beta of 0.43.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IMRX. PVG Asset Management Corp bought a new position in Immuneering in the 1st quarter worth approximately $773,000. Empery Asset Management LP purchased a new stake in Immuneering during the 4th quarter valued at approximately $17,601,000. Blue Owl Capital Holdings LP raised its position in shares of Immuneering by 20.9% during the fourth quarter. Blue Owl Capital Holdings LP now owns 665,000 shares of the company’s stock valued at $4,376,000 after buying an additional 115,000 shares during the last quarter. 683 Capital Management LLC bought a new stake in shares of Immuneering during the fourth quarter valued at approximately $992,000. Finally, DCF Advisers LLC purchased a new position in shares of Immuneering in the fourth quarter worth $1,415,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.